RxDoctor Payments Data

Elena Dembo-Smeaton, MD

Family Medicine · la Jolla, CANPI 1184795296

Payments from drug & device makers

$4,974in general payments, 2019–2025

Across 230 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$608
  • GSK$380
  • Lilly USA, LLC$317
  • Pfizer$220
  • Novo Nordisk$178
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$4,90999%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,974 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$35,514
Medicare patients
125
Services billed
510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol22$33,020
EliquisApixaban36$26,292
InvokanaCanagliflozin12$6,529
Hydrocodone-IbuprofenHydrocodone/Ibuprofen13$4,174
SynthroidLevothyroxine Sodium43$2,482
Levothyroxine Sodium178$2,166
Atorvastatin Calcium250$2,104
Losartan Potassium134$1,451
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide67$1,391
Wixela InhubFluticasone Propion/Salmeterol13$1,317
Gabapentin67$1,203
Rosuvastatin Calcium58$924
Metformin Hcl88$835
Nebivolol Hcl12$784
Albuterol Sulfate HfaAlbuterol Sulfate30$762

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,063$33,02022 claims
PfizerEliquis$220$26,29236 claims
Johnson & JohnsonInvokana$157$6,52912 claims
AbbVieSynthroid$608$2,48243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →